Moura B.,Departement dOncologie |
Migliorin D.,Center doncologie |
Bourhis J.,Departement dOncologie |
Daniel R.,CHUV |
And 2 more authors.
Revue Medicale Suisse | Year: 2016
Gliomas represent two thirds of all primary brain tumors. Their prognosis depends directly upon their level of differentiation. On MRI, tumoral aggressivity is highlighted by contrast uptake and the infiltrative nature of the lesion. Clinical suspicion must however be confirmed by histology and molecular markers become essential to refine the diagnosis and tailor the treatment. Isocytrate dehydrogenase (IDH) mutations, codeletion of 1p and 19q and the presence of methylation of the MGMT promoter identify a subgroup of gliomas with better prognosis and may help predict response to treatment. Management of patients with primary brain tumors should always be defined in multidisciplinar tumor boards involving neurosurgeons, oncologists, radiation oncologists, neuropathologists and neuroradiologists.
Migliorini D.,Center doncologie |
Dietrich P.-Y.,Center doncologie
Revue Medicale Suisse | Year: 2016
Glioblastomas are highly aggressive tumors. Their prognosis remain poor despite standard therapies combining surgery, radiation and temozolomide based chemotherapy. Among innovating strategies, there is a major interest for immunotherapy. During the past 3 decades, there has been a general scepticism concerning the efficacy of this approach. But the latest achievements, such as immune checkpoint inhibitors in solid tumors, and adoptive cell therapy in hematologic malignancies, have radically changed the face of the field and have already an impact on the daily practice. To which extent these advances have an impact for brain tumors also? This article aims to present the principal clinical applications of the various immune therapies currently under investigation in neurooncology and give an insight on the future perspectives in the field.
Pagani O.,Oncology Institute of Southern Switzerland IOSI |
Pagani O.,Oncology Institute |
Ruggeri M.,Oncology Institute |
Manunta S.,Oncology Institute of Southern Switzerland IOSI |
And 20 more authors.
Breast | Year: 2015
Young patients with breast cancer (BC) are often concerned about treatment-induced infertility and express maternity desire. Conception after BC does not seem to affect outcome, but information in estrogen-receptor positive (ER+) disease is not definitive. From September 2012-March 2013, 212 evaluable patients with ER+ early BC, <37years at diagnosis, from 5 regions (Europe/US/Canada/Middle-East/Australia) answered a survey about fertility concerns, maternity desire and interest in a study of endocrine therapy (ET) interruption to allow pregnancy. Overall, 37% of respondents were interested in the study; younger patients (≤30 years) reported higher interest (57%). Motivation in younger patients treated >30 months was higher (83%) than in older women (14%), interest was independent of age in patients treated for ≤30 months. A prospective study in this patient population seems relevant and feasible. The International-Breast-Cancer-Study-Group (IBCSG), within the Breast-International-Group (BIG) - North-American-Breast-Cancer-Groups (NABCG) collaboration, is launching a study (POSITIVE) addressing ET interruption to allow pregnancy. © 2015 Elsevier Ltd.
Haddad H.,Center doncologie |
Sellal N.,Center doncologie |
Bourhaleb Z.,Center doncologie
Progres en Urologie | Year: 2014
The prostate is a very rare localization of signet ring cell carcinoma, with few cases reported in the literature. This histological type occurs rather in cancers of the digestive tract (stomach, colon). Authors report a case of a patient aged 63. years. Diagnostic and therapeutic features are discussed. © 2013 Elsevier Masson SAS.
Ismaili N.,Center doncologie |
Elmajjaoui S.,Institute National dOncologie |
Bensouda Y.,Institute National dOncologie |
Belbaraka R.,Center doncologie |
And 12 more authors.
Oncology Reviews | Year: 2011
Bladder cancer is the fourth most common cancer for men and the eighth most common cancer for women. Transitional cell carcinoma is the most predominant histological type. Bladder cancer is highly chemosensitive. In metastatic setting the treatment is based on cisplatin chemotherapy regimens type MVAC, MVAC-HD or gemcitabine plus cisplatin. The standard treatment of muscle invasive operable bladder cancer (T2-T4) used widely was radical cystectomy with pelvic lymph nodes dissection; the anatomical extent of pelvic lymphadenectomy has not accurately been defined so far. However, in the last decade, the treatment of tumors was improved by the introduction of chemotherapy as part of the management of the disease. Neoadjuvant chemotherapy should be considered at first, as standard treatment of choice, before local treatment for patients with good performance status (0-1) and good renal function-glomerular filtration rate (GFR) >60 mL/min. For patients treated with primary surgery, adjuvant chemotherapy is a valuable option in the case of lymph nodes involvement. This brief review would provide the evidence of the role of neoadjuvant chemotherapy in the management of operable muscle invasive (T2-T4) bladder cancer. © Springer-Verlag 2011.